• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

13.21 -0.02 (-0.15%)
Official Closing Price Updated: 4:10 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,909,242
Open 13.52
Bid (Size) 12.00 (500)
Ask (Size) 13.99 (80,500)
Prev. Close 13.23
Today's Range 13.18 - 13.57
52wk Range 11.36 - 15.67
Shares Outstanding 166,301,231
Dividend Yield 0.63%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Dr. Reddy's Laboratories Q2 Earnings Call Highlights ↗
Today 14:04 EDT
Dr. Reddy's Laboratories (NYSE:RDY) reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American... 
Via MarketBeat
Topics Earnings
News headline image
Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript ↗
Today 12:43 EDT
Revenue declined 1.5% as Lenalidomide sales fell, but emerging markets surged 84%. 
Via The Motley Fool
Topics Earnings

Performance

52-Week Range 15.7% below 52-week high
13.21
11.3652W Low 15.6752W High
1 Week 1.0% below 1-week high
12.941W Low 13.351W High

Dr. Reddy's Laboratories Ltd Common Stock (RDY) traded between $11.36 and $15.67 over the past 52 weeks and last traded at $13.21, 15.7% below its 52-week high. Over the past week it ranged between $12.94 and $13.35.

Past 12 Months
+1.1%
+5.1%
+11.9%
-2.7%
-4.7%
-11.2%
1W +$0.14
1M +$0.64
3M +$1.41
6M -$0.37
YTD -$0.65
1Y -$1.66

RDY was -11.2% over the past year, -2.7% over six months, -4.7% year to date, +1.1% in the last week.

12 Months vs Market
RDY
-11.2%
DIA
+11.9%
SPY
+13.8%
QQQ
+16.3%
IWM
+13.3%

Over the past 12 months RDY returned -11.2% versus DIA (Dow) +11.9%, SPY (S&P 500) +13.8%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.3%.

Volume & Liquidity 1.33× 3-mo avg
Today 3,909,242 3-mo avg 2.9M
1W
2.9M
1M
3.2M
3M
2.9M
6M
2.8M
YTD
2.5M
1Y
2.3M

RDY most recently traded 3,909,242 shares against a 3-month average daily volume of 2.9M.

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
September 22, 2026
From Pomerantz LLP
Via GlobeNewswire
Dr. Reddy's Laboratories (NYSE:RDY): A Peter Lynch GARP Candidate in the Pharmaceuticals Space ↗
May 11, 2026
Via Chartmill
Peter Lynch's GARP Strategy Identifies DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) as a Candidate ↗
April 20, 2026
Via Chartmill
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Passes Key Peter Lynch Investment Screen ↗
March 28, 2026
Via Chartmill
DR. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch GARP Investment Strategy ↗
February 27, 2026
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
September 15, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
September 08, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
September 01, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
August 25, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
August 20, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Dr. Reddy’s Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
August 20, 2026
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 19, 2026
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
RDY SHAREHOLDER ALERT: Dr. Reddy’s Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
August 13, 2026
From Kirby McInerney LLP
Via Business Wire
News headline image
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
August 04, 2026
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy’s Laboratories (RDY)
July 28, 2026
From Levi & Korsinsky
Via Business Wire
News headline image
Dr. Reddy's Laboratories Q1 Earnings Call Highlights ↗
July 22, 2026
Via MarketBeat
Topics Earnings
News headline image
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk ↗
July 12, 2026
Via MarketBeat
News headline image
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call ↗
July 01, 2026
Via Benzinga
Topics Earnings
News headline image
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
June 26, 2026
From Dr. Reddy’s Laboratories Limited
Via Business Wire
News headline image
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
June 13, 2026
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
May 16, 2026
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Q4 Earnings Call Highlights ↗
May 14, 2026
Via MarketBeat
Topics Earnings
News headline image
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
April 29, 2026
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire

Frequently Asked Questions

Is Dr. Reddy's Laboratories Ltd Common Stock publicly traded?
Yes, Dr. Reddy's Laboratories Ltd Common Stock is publicly traded.
What exchange does Dr. Reddy's Laboratories Ltd Common Stock trade on?
Dr. Reddy's Laboratories Ltd Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Dr. Reddy's Laboratories Ltd Common Stock?
The ticker symbol for Dr. Reddy's Laboratories Ltd Common Stock is RDY on the New York Stock Exchange
What is the current price of Dr. Reddy's Laboratories Ltd Common Stock?
The current price of Dr. Reddy's Laboratories Ltd Common Stock is 13.21
When was Dr. Reddy's Laboratories Ltd Common Stock last traded?
The last trade of Dr. Reddy's Laboratories Ltd Common Stock was at 10/23/26 04:10 PM ET
What is the market capitalization of Dr. Reddy's Laboratories Ltd Common Stock?
The market capitalization of Dr. Reddy's Laboratories Ltd Common Stock is 2.20B
How many shares of Dr. Reddy's Laboratories Ltd Common Stock are outstanding?
Dr. Reddy's Laboratories Ltd Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap